Dr. Kenneth Aldape from the U.S. National Cancer Institute Joins Pangea Biomed’s Scientific Advisory Board
Dr. Aldape will work alongside the biotech company to guide the advancement of their cancer response predictor platform
Tel Aviv, Israel – WEBWIRE – Wednesday, October 2, 2024
Pangea Biomed, the startup behind the worlds most advanced cancer response predictor, ENLIGHT, announced that Dr. Kenneth D. Aldape, M.D., has joined the companys scientific advisory board.
Dr. Aldape, a globally recognized molecular neuropathologist, is Chief of the National Cancer Institute (NCI) Lab of Pathology. He is a leading figure in his field, esteemed for his influential work using methylation patterns (chemical modifications) for the sub-classification of brain tumors, which is considered the most accurate tool for brain tumor diagnosis.
Weve been collaborating with Dr. Aldape for years, around NCI trials to test our ENLIGHT platform, explained Pangea CEO Tuvik Beker. Now, with him on our scientific advisory board, were excited for his strategic expertise and input in shaping the direction of our research and development efforts.
Dr. Aldape has previously held faculty positions at the University of California, San Francisco, at MD Anderson Cancer Center, where he served as department chair of pathology and at Princess Margaret Cancer Centre, where he served as a senior scientist. He is recognized as a leader in the use of molecular technologies to advance precision tumor diagnostics.
As an advisor to Pangea, I look forward to gaining an even better understanding of the capabilities of improved cancer diagnostics and treatments for patients, said Dr. Aldape. As we work closely together, we hope to generate new technologies that contribute to patient welfare.
Dr. Aldapes role as a Pangea scientific advisory board member is recognized as part of his official duties by The National Institutes of Health (NIH), ensuring it aligns with his responsibilities within the organization and in external collaborations.
Dr. Aldapes appointment to Pangeas scientific advisory board closely follows that of Dr. Lillian Siu, a senior medical oncologist at Princess Margaret Cancer Centre, professor of medicine at the University of Toronto and the current president of the American Association for Cancer Research (AACR).
In addition to Dr. Aldape and Dr. Siu, the scientific advisory board includes:
Raanan Berger, MD, Ph.D., Director of the Cancer Center at Sheba Medical Center
J. Silvio Gutkind, Ph.D., Professor and Chair of the Department of Pharmacology at UCSD School of Medicine and Associate Director for Basic Science at Moores Cancer Center
Dan A. Landau, MD, Ph.D., Assistant Professor at Weill Cornell Medical College and Core Member at the New York Genome Center
Gideon Rechavi, MD, Ph.D., head of Sheba Cancer Research Center and head of the Wohl Institute for Translational Medicine
Zeev Ronai, Ph.D., Director of the NCI-Designated Cancer Center at Sanford Burnham Prebys Discovery Institute
Eytan Ruppin, MD, Ph.D., Chief of the Cancer Data Science Lab at the National Cancer Institute
To learn more about Pangea and ENLIGHT, please visit https://pangeabiomed.com
About Pangea Biomed
Founded in 2018, Pangea Biomed developed ENLIGHT the worlds most advanced multi-cancer, multi-therapy response predictor. By combining machine learning and deep RNA analysis, the company is mapping tumor molecular signatures to dynamically and adaptively personalize cancer care for a healthier world. Pangea aims to bring effective precision oncology to cancer patients, improve oncology drug development and empower oncologists to treat patients with success. Pangea is backed by NFX, and its technology has been published in leading journals, including Cell, Med, Science Advances, Cancer Cell, Journal for ImmunoTherapy of Cancer and Nature Communications.
( Press Release Image: https://photos.webwire.com/prmedia/42381/327575/327575-1.png )
WebWireID327575
Contact Information
VSC
Media Contact
VSC for Pangea Biomed
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.
